WuXi NextCode, a genome sequencing analysis business with ties to China-based contract research organization WuXi PharmaTech, has completed a $240 million extended Series B round of funding led by Sequoia China and featuring Temasek Holdings, Yunfeng Capital and 3W Partners.
The Series A round was raised when the company was established in 2015, with WuXi PharmaTech contributing most of the capital, alongside Amgen Ventures, a VC fund established by biopharmaceutical player...
Most traditional large-cap buyout funds have become hybrids in Asia, taking minority stakes in businesses to generate deal flow in certain markets and to harness regional growth trends
Addor Capital – a Chinese VC firm backed by Jiangsu High-Tech Investment Group, also known as Govtor Capital – has raised RMB1.56 billion ($241 million) for its second renminbi-denominated healthcare fund.
India’s Trifecta Capital has closed its second venture debt fund with $140 million in commitments. The firm raised about $68.4 million for its debut vehicle in 2017.
Gitai, a Japanese start-up developing a humanoid general-purpose work robot for use in space, has secured a JPY1.8 billion ($17 million) Series B round from local VCs.